Wedbush started coverage on shares of Orchard Therapeutics (NASDAQ:ORTX) in a research report report published on Sunday morning. The brokerage issued an outperform rating and a $16.80 target price on the stock.

Several other equities research analysts also recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an overweight rating and a $25.00 price objective for the company. Goldman Sachs Group assumed coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set a neutral rating and a $18.00 price objective for the company. Finally, Cowen assumed coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an outperform rating and a $27.00 price objective for the company.

Shares of NASDAQ:ORTX opened at $14.80 on Friday. Orchard Therapeutics has a 52 week low of $13.00 and a 52 week high of $19.24.

Orchard Therapeutics Company Profile

There is no company description available for Orchard Therapeutics PLC.

Further Reading: What is the LIBOR?

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.